ATE554827T1 - Pharmazeutische zusammensetzung mit einem antitumoralen mittel und einem insbesondere aus carveol, thymol und carvacrol ausgewählten wirkstoff - Google Patents

Pharmazeutische zusammensetzung mit einem antitumoralen mittel und einem insbesondere aus carveol, thymol und carvacrol ausgewählten wirkstoff

Info

Publication number
ATE554827T1
ATE554827T1 AT06744739T AT06744739T ATE554827T1 AT E554827 T1 ATE554827 T1 AT E554827T1 AT 06744739 T AT06744739 T AT 06744739T AT 06744739 T AT06744739 T AT 06744739T AT E554827 T1 ATE554827 T1 AT E554827T1
Authority
AT
Austria
Prior art keywords
carveol
carvacrol
thymol
pharmaceutical composition
active ingredient
Prior art date
Application number
AT06744739T
Other languages
English (en)
Inventor
Adnane Remmal
Original Assignee
Advanced Scient Developements
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developements filed Critical Advanced Scient Developements
Application granted granted Critical
Publication of ATE554827T1 publication Critical patent/ATE554827T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06744739T 2005-05-13 2006-05-15 Pharmazeutische zusammensetzung mit einem antitumoralen mittel und einem insbesondere aus carveol, thymol und carvacrol ausgewählten wirkstoff ATE554827T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2005/001314 WO2006120495A1 (fr) 2005-05-13 2005-05-13 Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
PCT/IB2006/001328 WO2006120564A1 (fr) 2005-05-13 2006-05-15 Composition pharmaceutique comprenant un antiviral , un antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol , le thymol, l' eugenol, le borneol et le carvacrol

Publications (1)

Publication Number Publication Date
ATE554827T1 true ATE554827T1 (de) 2012-05-15

Family

ID=35427309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06744739T ATE554827T1 (de) 2005-05-13 2006-05-15 Pharmazeutische zusammensetzung mit einem antitumoralen mittel und einem insbesondere aus carveol, thymol und carvacrol ausgewählten wirkstoff

Country Status (16)

Country Link
US (2) US20080171709A1 (de)
EP (2) EP1879656B1 (de)
JP (1) JP5073651B2 (de)
CN (2) CN101175532B (de)
AP (1) AP2437A (de)
AT (1) ATE554827T1 (de)
BR (2) BRPI0610130A2 (de)
CA (2) CA2606887C (de)
DK (2) DK1883452T3 (de)
EA (1) EA015168B1 (de)
ES (2) ES2386292T3 (de)
MA (2) MA29573B1 (de)
PT (2) PT1883452E (de)
TN (2) TNSN07426A1 (de)
WO (3) WO2006120495A1 (de)
ZA (1) ZA200710785B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113042A1 (en) * 2006-09-05 2008-05-15 Chu Kee Hung Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof
US20080293648A1 (en) * 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
US8563554B2 (en) 2009-03-17 2013-10-22 Concert Pharmaceuticals, Inc. Deuterated pyrazinoisoquinoline compounds
JP5844260B2 (ja) 2009-09-24 2016-01-13 ユニリーバー・ナームローゼ・ベンノートシヤープ オイゲノール、テルピネオールおよびチモールを含む殺菌剤
US9408870B2 (en) 2010-12-07 2016-08-09 Conopco, Inc. Oral care composition
EA024551B1 (ru) 2011-11-03 2016-09-30 Юнилевер Н.В. Индивидуальная композиция для очищения
CN102579449B (zh) * 2012-03-30 2013-08-07 厦门大学 一种可提高肿瘤对紫杉醇敏感性的联合用药
GB201404505D0 (en) * 2013-09-06 2014-04-30 Mars Inc Oral anti-parasitic composition
CA2959414C (en) 2014-09-05 2023-03-14 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
US20180078515A1 (en) * 2015-03-20 2018-03-22 Sammy Oyoo OPIYO Use of suramin and arginase inhibitors in malignant neoplasia
WO2016196653A1 (en) 2015-06-01 2016-12-08 Symbiomix Therapeutics, Llc Novel nitroimidazole formulations and uses thereof
CN105147647A (zh) * 2015-08-19 2015-12-16 华南理工大学 右旋龙脑作为抗肿瘤药物增敏剂的应用
MA44286A (fr) 2016-06-02 2019-01-09 Advanced Scient Developements Formulation pharmaceutique de cinéol et d'amoxicilline
CN110650739A (zh) * 2017-03-28 2020-01-03 Irp健康股份有限公司 小檗碱生物碱在预防和/或治疗肠疾病中的作用
EP4208157A1 (de) 2020-09-04 2023-07-12 Elanco Us Inc. Wohlschmeckende formulierungen
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
CN112972437B (zh) * 2021-02-19 2022-03-25 沈阳伟嘉生物技术有限公司 一种包含碘硝酚的长效外用制剂及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
DE19509697A1 (de) * 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JP2002531511A (ja) * 1998-12-07 2002-09-24 エコスマート テクノロジーズ,インコーポレーテッド シグナル伝達調節物質と天然植物精油を用いた癌治療薬配合物および方法
US6536268B1 (en) * 1999-11-01 2003-03-25 Siemens Vdo Automotive Corporation Utilizing increasing width for identification voltages
DE10007771A1 (de) * 2000-02-14 2001-08-23 Kleine & Steube Entoxin Gmbh Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2791302A (en) * 2000-11-09 2002-05-21 Jorg P Schur Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
WO2003069993A1 (en) * 2002-02-20 2003-08-28 Pharmessen Scientific, Inc. Antimicrobial therapeutic compositions and methods of use
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
AP2005003346A0 (en) * 2002-12-10 2005-06-30 Biosynexus Inc Topical anti-infective formulations
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CN100343223C (zh) * 2005-03-07 2007-10-17 常州市智能动物药业有限公司 百里酚或香芹酚的酯类化合物、制备方法及其药物活性组合物

Also Published As

Publication number Publication date
MA29573B1 (fr) 2008-06-02
EP1883452B1 (de) 2012-12-19
JP5073651B2 (ja) 2012-11-14
AP2437A (en) 2012-08-31
ES2386292T3 (es) 2012-08-16
EA200702486A1 (ru) 2008-06-30
CA2608061A1 (fr) 2006-11-16
WO2006120564A1 (fr) 2006-11-16
DK1883452T3 (da) 2013-02-25
CN101175532A (zh) 2008-05-07
MA29908B1 (fr) 2008-11-03
PT1883452E (pt) 2013-02-18
WO2006120568A3 (fr) 2007-08-23
US20080171768A1 (en) 2008-07-17
EA015168B1 (ru) 2011-06-30
BRPI0610130A2 (pt) 2012-09-25
CA2608061C (fr) 2014-07-15
ES2399348T3 (es) 2013-03-27
BRPI0610123A2 (pt) 2012-09-25
CN101193682B (zh) 2012-06-13
WO2006120495A1 (fr) 2006-11-16
TNSN07423A1 (fr) 2009-03-17
CN101193682A (zh) 2008-06-04
AP2007004228A0 (en) 2007-12-31
US20080171709A1 (en) 2008-07-17
CN101175532B (zh) 2011-12-28
EP1879656A1 (de) 2008-01-23
EP1883452A2 (de) 2008-02-06
CA2606887A1 (fr) 2006-11-16
PT1879656E (pt) 2012-07-25
DK1879656T3 (da) 2012-07-23
WO2006120568A2 (fr) 2006-11-16
ZA200710785B (en) 2009-06-24
JP2008540505A (ja) 2008-11-20
EP1879656B1 (de) 2012-04-25
CA2606887C (fr) 2014-07-15
TNSN07426A1 (fr) 2009-03-17

Similar Documents

Publication Publication Date Title
ATE554827T1 (de) Pharmazeutische zusammensetzung mit einem antitumoralen mittel und einem insbesondere aus carveol, thymol und carvacrol ausgewählten wirkstoff
PL3075401T3 (pl) Środek konserwujący dla kompozycji kosmetycznych, toaletowych i farmaceutycznych
IL192967A0 (en) Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
IL221770A (en) Edamantyl acetamide derivatives, the pharmaceutical composition containing them and its use in the preparation of a drug
IL228402A0 (en) Nitro-cyclic compounds, their pharmaceutical preparations and their uses
IL193678A (en) Derivatives of pyrazolyl-theophane, pharmaceuticals containing them and their use in the preparation of drugs to improve cognitive activity
IL195491A (en) Pharmaceutical compositions of tmc278 and processes for their preparation
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
IL188732A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
IL177533A (en) Benzimidazole derivatives, their preparation and pharmaceutical compositions comprising them
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
IL188744A0 (en) High drug load formulations and dosage forms
WO2010021607A3 (en) Pharmaceutical formulation
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
IL217897A0 (en) Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.
EP2015740A4 (de) Neue niedrigdosierte pharmazeutische zusammensetzungen mit nimesulid, zubereitung und verwendung
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
BRPI0909296A2 (pt) uso de pelo menos um princípio ativo, e, composições cosmética, farmacêutica e/ou dermatológica
IL192206A0 (en) Topical mecamylamine formulations for ocular administration and uses thereof